Oral anticoagulant accepted for NHS use after acute coronary syndromes

Rivaroxaban (Xarelto) has been accepted by NICE for preventing adverse outcomes after acute management of acute coronary syndromes.

Acute coronary syndromes include myocardial infarction (shown) and unstable angina. SCIENCE PHOTO LIBRARY
Acute coronary syndromes include myocardial infarction (shown) and unstable angina. SCIENCE PHOTO LIBRARY

In its latest technology appraisal of rivaroxaban, NICE recommends the direct oral factor Xa inhibitor as an option, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in people who have had an acute coronary syndrome and have elevated cardiac biomarkers.

Further information
NICE technology appraisal TA335

The risk of bleeding needs to be assessed before rivaroxaban is initiated and a decision on continuation of treatment should be taken after no more than 12 months.

Rivaroxaban has previously been accepted by NICE for the prevention of VTE after hip or knee replacement, the treatment and prevention of DVT and pulmonary embolism and the prevention of stroke in patients with atrial fibrillation.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more